Treatment of Male Hypogonadism With Testosterone Undecanoate Injected at Extended Intervals of 12 Weeks: A Phase II Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This paper reports the result of an open‐label, nonrandomized clinical trial investigating the efficacy and safety of an injectable preparation of testosterone undecanoate (TU) dissolved in castor oil and given over a 3.2‐year period. In a previous study we demonstrated that injections of TU every 6 weeks resulted in satisfactory substitution but a tendency toward testosterone accumulation. Here we investigate prolonged TU treatment at extended injection intervals in 7 hypogonadal men. Injections were given at gradually increasing intervals between the fifth and 10th injection, and from then on every 12 weeks. Steady state kinetics were obtained after the 13th injection. Well‐being, sexual activity, clinical chemistry, prostate volume, and prostate‐specific antigen (PSA) and serum hormone levels were monitored. Patients were clinically well‐adjusted throughout the study. Before the next injection, testosterone, dihydrotestosterone, and estradiol levels were mostly within the normal range and showed a tendency to decrease with increasing injection intervals. Body weight, hemoglobin, serum lipids, PSA, and prostate volume did not change significantly during the 3.2 years of treatment. PSA levels were always within the normal limit. Maximal testosterone levels during steady state kinetics were measured after 1 week with 32.0 ± 11.7 nmol/L (mean ± SD). Before the last injection, mean testosterone concentrations were 12.6 ± 3.7 nmol/L. Compared with conventional testosterone enanthate or cypionate treatment requiring injection intervals of 2–3 weeks and resulting in supraphysiological serum testosterone levels, injections of TU at intervals of up to 3 months offer an excellent alternative for substitution therapy of male hypogonadism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Effects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464
Dobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381
Zitzmann, M., & Nieschlag, E. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440183 · Cited by 248
Self-citationNieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
Self-citation
Cited by
Lanfranco, F., Kamischke, A., Zitzmann, M., & Nieschlag, E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16678-6 · Cited by 1,002
Self-citationRisks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
The benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Kalinchenko, S. Y., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J. G., Giltay, E. J., & Saad, F. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03845.x · Cited by 341
Testosterone replacement therapy: current trends and future directions
Nieschlag, E., Behre, H. M., Bouchard, P., Corrales, J. J., Jones, T. H., Stalla, G. K., Webb, S. M., & Wu, F. C. W. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh035 · Cited by 224
Self-citation
Metadata
- Authors
- VON ECKARDSTEIN, S., & NIESCHLAG, E.
- Venue
- Journal of Andrology
- Publisher
- Wiley
- Published
- 2002-05-06
- Volume
- 23
- Issue
- 3
- Pages
- 419-425
- ISSN
- 0196-3635 (ISSN-L)
- 1939-4640
- OpenAlex
- W2104192915
- Cited by
- 146
- References
- 5
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.